The kidney transplant program at king faisal specialist hospital and research center.

Saudi J Kidney Dis Transpl

Director, Renal Transplant Program, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Published: October 2012

The Kidney Transplant Program at the King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh was launched in 1981 when the first living-donor (LD) kidney transplant was performed in the center. The first deceased-donor (DD) kidney transplant was performed in 1982, and the first simultaneous kidney-pancreas (SPK) in 2004. As of February 2005, more than 1,000 kidney transplants (654 living-donor and 347 deceased-donor) have been performed. The Renal Transplant Program at KFSH&RC underwent a major transformation in the year 2001 with the introduction of the concept of designated Renal Transplant Physicians and the emphasis on multi-disciplinary teamwork. This core team of highly qualified, experienced and dedicated physicians worked along side their colleagues, the Renal Transplant Surgeons, to pursue state-of-the-art kidney and pancreas transplantation. A new theme of true collaboration and shared vision was born. This fundamental change has resulted in tripling of the size of the program and in expanding its scope of services to include high-risk patients (immunological and surgical). The above achievements were coupled with outstanding outcome data. The Kidney Transplant Program at KFSH&RC is now a leading transplant center in the region in terms of size and scope of services and it measures up to the top 10% of the leading kidney transplant centers in the world in terms of size, scope of services, and outcome measures. The current program is a multi-disciplinary program composed of three Consultant Surgeons, two Consultant Renal Transplant Physicians, one Associate Consultant Surgeon, two Assistant Consultant Surgeons, two Assistant Consultant Transplant Physicians, two Clinical Co-ordinators, one Nurse Clinician, one Administrative Co-ordinator, one Clinical Pharmacist, one Health Educator, one Social Worker and a qualified Immunologist with HLA/Immunopathology staff.

Download full-text PDF

Source

Publication Analysis

Top Keywords

kidney transplant
24
transplant program
16
renal transplant
16
transplant physicians
12
scope services
12
transplant
11
kidney
8
program king
8
king faisal
8
faisal specialist
8

Similar Publications

Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport Syndrome.

Nephrol Dial Transplant

January 2025

Department of Nephrology, Kidney Transplantation and Dialysis, CHU Lille, University of Lille, Lille, France.

Background And Hypothesis: Unlike X-linked or autosomal recessive Alport Syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4.

Methods: We carried out a multicenter retrospective study to assess the risk factors involved in renal survival in patients presenting a single pathogenic variant on COL4A3 or COL4A4.

Results: 97 patients presenting a single pathogenic variant of COL4A3 or COL4A4 were included.

View Article and Find Full Text PDF

N-Acetylcysteine and Liver Transplant. Advantages of its Administration in Multi-Organ Donors Especially During World-Economical-Crisis. Long-Term Sub-Group Analysis in a Randomized Study.

Transplant Proc

January 2025

Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital of Padua, Padua, Italy; Dipartimento di Medicina di Precisione e Rigenerativa e Area Jonica (DiMePRe-J) Bari University; Department of Surgery, Yale University School of Medicine, New Haven, Connecticut. Electronic address:

Background: Liver transplantation (LT) is the main indication for the treatment of end-stage liver disease but have to face organ shortages. Using marginal donors is an option to increase the donor pool. Previous studies showed that the graft procured using N-acetylcysteine (NAC) provides a longer survival compared to perfusion with standard solutions, especially in marginal liver donors.

View Article and Find Full Text PDF

Belatacept was introduced as an immunosuppressant for kidney transplantation in 2010, but its use in Spain remains limited. Since its commercialization, 15 kidney transplant recipients have received immunosuppressive treatment with belatacept at the Cruces University Hospital. This observational and retrospective study analyzes the reasons for switching to belatacept, its impact on kidney function, and the drug's safety profile.

View Article and Find Full Text PDF

Syndecan-1 in the Serum of Deceased Kidney Donors as a Potential Biomarker of Kidney Function.

Transplant Proc

January 2025

Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic; Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; Faculty of Health Studies, Technical University in Liberec, Liberec, Czech Republic.

Background: The process of kidney transplantation remains the optimal treatment for end-stage renal disease, offering improved quality of life and increased survival rates compared to long-term dialysis. However, despite advances in surgical techniques, immunosuppression regimens, and post-operative care, there are still significant challenges in predicting the organ's status and long-term outcomes of transplantation. Among the many factors that influence graft survival, the quality of the donated organ plays a fundamental role.

View Article and Find Full Text PDF

In Germany, around 80000 people are currently dependent on permanent renal replacement therapy (RRT). Due to demographic developments and improvements in life expectancy, the prevalence will continue to increase even if the effects of newer pharmacological substances such as SGLT2 inhibitors and GLP1 agonists are promising in inhibiting progression. There are basically three different methods of renal replacement therapy and their variants: Kidney transplantation (KTX), peritoneal dialysis (PD), hemodialysis (HD)/hemodiafiltration (HDF).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!